Comparative Pharmacology
Head-to-head clinical analysis: ADVIL PM versus INDOMETHACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL PM versus INDOMETHACIN.
ADVIL PM vs INDOMETHACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Diphenhydramine is a first-generation antihistamine that antagonizes histamine H1 receptors, causing sedation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Two caplets (ibuprofen 200 mg, diphenhydramine citrate 38 mg) orally at bedtime as needed for insomnia. Maximum: 2 caplets in 24 hours.
25-50 mg orally 2-3 times daily; maximum 200 mg/day. Also available as 75 mg sustained-release capsule orally once daily, or 50 mg rectally 3-4 times daily.
None Documented
None Documented
Clinical Note
moderateIndomethacin + Gatifloxacin
"Indomethacin may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIndomethacin + Rosoxacin
"Indomethacin may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIndomethacin + Levofloxacin
"Indomethacin may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIndomethacin + Trovafloxacin
Ibuprofen: 2-4 hours (terminal); clinical context: steady state achieved in 1 day, not affected by renal impairment. Diphenhydramine: 4-8 hours (terminal); clinical context: prolonged in hepatic impairment.
Terminal elimination half-life is approximately 4.5 hours (range 2.6-11.2 hours) in adults; prolonged in neonates (up to 17 hours) and in patients with renal impairment or cholestasis; clinical context: dosing interval adjustments needed in hepatic or renal disease.
Ibuprofen: Renal (90% as metabolites and conjugates, <10% unchanged); Diphenhydramine: Renal (primarily as metabolites, ~1% unchanged). Fecal excretion is negligible for both.
Renal excretion of unchanged drug and metabolites (approximately 60% as parent drug and glucuronide conjugate; 23% as O-desmethyl metabolite; 13% as glucuronide of O-desmethyl metabolite); biliary/fecal elimination accounts for 30-40%, primarily as glucuronide conjugates.
Category C
Category D/X
NSAID/Sedative Combination
NSAID
"Indomethacin may increase the neuroexcitatory activities of Trovafloxacin."